A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies
Latest Information Update: 22 Feb 2023
At a glance
- Drugs Pembrolizumab (Primary) ; Lenalidomide
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-013
- Sponsors Merck & Co; Merck Sharp & Dohme
- 01 Jan 2023 Results (of Cohort 4, n=89 and Cohort 5, n=19) assessing safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL published in the Leukemia and Lymphoma
- 01 Jul 2022 Results (n=28; by 26 Jun 2020) from MDS cohort of this trial published in the Leukemia and Lymphoma
- 17 Jun 2022 Results from four KEYNOTE-013 (NCT01953692, n=20), KEYNOTE-087 (NCT02453594, n=31), KEYNOTE-170 (NCT02576990, n=5), and KEYNOTE-204 (NCT02684292) trials presented at the 27th Congress of the European Haematology Association